TrialArthritis research & therapy2019

Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.

Vibeke Strand et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.